
|Poll|November 21, 2011
A 29-Year-Old Man Presents With Stage IV, Poorly Differentiated Malignant Melanoma
Author(s)Ted Rosen, MD
Advertisement
A 29-year-old man was
Aside from palliative resection of the bulky tumor mass, what newly approved drug might now be considered as a therapeutic option for this otherwise young, healthy individual?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
2
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
3
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
4
What is the Future of TIL Therapy in Metastatic Melanoma?
5



















































